Vertex nearing goal on hepatitis C drug
Cambridge firm locked in battle with Merck & Co.
After years of developing what it hopes will be a blockbuster drug to treat the hepatitis C virus, Vertex Pharmaceuticals Inc. of Cambridge is rapidly closing in on its goal: a product that could generate billions of dollars in annual revenue. (Full article: 761 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
